| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
5WKS targets G9a (EHMT2), a nuclear histone lysine methyltransferase that catalyzes the dimethylation of histone H3 at lysine 9 (H3K9me2). This histone modification is generally associated with transcriptional gene silencing. By inhibiting G9a, 5WKS blocks the methylation of H3K9, leading to the reactivation of silenced genes. G9a is implicated in various pathological conditions, including cancer and autoimmune diseases, where it contributes to the silencing of tumor suppressor genes or genes involved in immune regulation. 5WKS is a potent and selective inhibitor of G9a, making it a valuable tool for studying the role of this methyltransferase in gene regulation and disease.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that 5WKS effectively inhibits G9a activity, leading to reduced H3K9me2 levels in cells. This inhibition results in the reactivation of genes that are silenced by G9a-mediated methylation. 5WKS has been shown to modulate gene expression profiles in various cancer cell lines and immune cells, supporting its potential in cancer and autoimmune disease research. The compound's potency and selectivity for G9a over other histone methyltransferases make it a valuable tool for epigenetic studies. 5WKS is typically used at concentrations that effectively inhibit G9a without causing significant cytotoxicity. Detailed IC50 values and specific in vitro activity data are available in the primary research literature.
|
| ln Vivo |
In vivo studies on 5WKS are limited, but the compound is used in research on autoimmune disorders and cancer. As a G9a inhibitor, 5WKS has the potential to modulate gene expression in vivo, leading to therapeutic effects in diseases where G9a-mediated gene silencing plays a role. Animal models of cancer and autoimmune diseases are used to evaluate the efficacy of 5WKS. The compound is typically administered orally or intraperitoneally, and its effects on tumor growth, immune cell function, and disease progression are assessed. However, specific in vivo data for 5WKS are not extensively documented in publicly available sources. Research-grade 5WKS is intended for laboratory use only.
|
| Enzyme Assay |
Non-cellular enzyme assays for 5WKS typically involve measuring the activity of purified G9a (EHMT2) enzyme in the presence of the compound. The assay uses histone H3 peptide or a recombinant histone H3 substrate, along with the cofactor S-adenosylmethionine (SAM) as the methyl donor. Methyltransferase activity is measured by detecting the incorporation of methyl groups into the substrate, typically using radioactive or fluorescence-based detection methods. 5WKS is tested at various concentrations to determine its IC50 for G9a inhibition. These assays may also be performed with other histone methyltransferases to assess the selectivity of 5WKS. Dose-response curves are generated, and IC50 values are calculated using non-linear regression analysis.
|
| Cell Assay |
In vitro cell-based assays for 5WKS typically use cancer cell lines or immune cells to assess the effects of G9a inhibition on gene expression and cell function. Cells are cultured in appropriate media and treated with 5WKS at various concentrations for defined periods (e.g., 24-72 hours). H3K9me2 levels are measured by Western blotting or ELISA to confirm target engagement. Gene expression changes are assessed by qRT-PCR or RNA-seq to identify genes reactivated by G9a inhibition. Cell viability, proliferation, and apoptosis are measured using standard assays such as MTT, colony formation, or flow cytometry. The compound's effects on immune cell function, such as T-cell activation or cytokine production, can also be assessed. 5WKS is typically dissolved in DMSO and diluted in culture medium, with DMSO controls included to account for solvent effects.
|
| Animal Protocol |
In vivo animal studies for 5WKS typically involve mouse models of cancer or autoimmune diseases. Tumor-bearing mice or disease model mice are treated with 5WKS at various doses, typically administered orally or intraperitoneally. Tumor volume, disease progression, and survival are monitored throughout the study. At the end of the experiment, tumors or tissues are collected for histological analysis and biomarker evaluation, including H3K9me2 levels and gene expression analysis. Immune cell populations and function may be assessed in autoimmune disease models. Body weight and general health parameters are monitored to assess tolerability. However, specific detailed protocols for 5WKS in vivo studies are not extensively documented in publicly available sources.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 5WKS are limited in publicly available sources. The compound has a molecular weight of 462.03 g/mol and is soluble in DMSO at 100 mg/mL (216.44 mM). As a small molecule, 5WKS is expected to be absorbed from the gastrointestinal tract and distributed to tissues. Its ability to inhibit G9a, a nuclear enzyme, suggests that it can penetrate cell membranes and reach its intracellular target. However, detailed PK parameters such as half-life, Cmax, AUC, and bioavailability have not been extensively reported. Research-grade 5WKS is intended for laboratory use only. Further pharmacokinetic studies are needed to fully characterize the compound's absorption, distribution, metabolism, and excretion.
|
| Toxicity/Toxicokinetics |
Toxicological data for 5WKS are limited in publicly available sources. As a research compound, 5WKS is intended for laboratory use only and is not for human consumption. Standard toxicological assessments, including acute and chronic toxicity studies, would be required for clinical development. However, these data are not publicly available. In vitro studies suggest that 5WKS can be used at concentrations that effectively inhibit G9a without causing significant cytotoxicity in various cell lines. The compound's safety profile in vivo has not been extensively characterized. As with all research chemicals, appropriate safety precautions should be taken when handling 5WKS.
|
| References | |
| Additional Infomation |
5WKS (also known as ZINC97756584 and G9a-IN-1) is a small-molecule inhibitor of G9a (EHMT2), a nuclear histone lysine methyltransferase that catalyzes H3K9me2, a modification associated with transcriptional gene silencing. It has the molecular formula C24H36ClN5O2 and CAS number 1350752-07-6. 5WKS is used in research on autoimmune disorders and cancer. By inhibiting G9a-mediated H3K9me2, 5WKS can reactivate silenced genes involved in tumor suppression or immune regulation. The compound is not approved for clinical use and is strictly a research tool for epigenetic studies. Its molecular weight is 462.03 g/mol.
|
| Molecular Formula |
C24H36CLN5O2
|
|---|---|
| Molecular Weight |
462.027944564819
|
| Exact Mass |
461.255
|
| Elemental Analysis |
C, 62.39; H, 7.85; Cl, 7.67; N, 15.16; O, 6.93
|
| CAS # |
1350752-07-6
|
| PubChem CID |
53474404
|
| Appearance |
Solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
529.3±50.0 °C at 760 mmHg
|
| Flash Point |
273.9±30.1 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.600
|
| LogP |
4.89
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
32
|
| Complexity |
557
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)N1CCC(CC1)NC2=NC(=NC3=CC(=C(C=C32)OC)OCCCN4CCCC4)Cl
|
| InChi Key |
GHTIAKXLWWMKSI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H36ClN5O2/c1-17(2)30-12-7-18(8-13-30)26-23-19-15-21(31-3)22(16-20(19)27-24(25)28-23)32-14-6-11-29-9-4-5-10-29/h15-18H,4-14H2,1-3H3,(H,26,27,28)
|
| Chemical Name |
2-chloro-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine
|
| Synonyms |
5WKS; 5-WKS; 5 WKS; ZINC9775658
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1644 mL | 10.8218 mL | 21.6436 mL | |
| 5 mM | 0.4329 mL | 2.1644 mL | 4.3287 mL | |
| 10 mM | 0.2164 mL | 1.0822 mL | 2.1644 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA